IGR Global Cardiovascular Implants Market | Page 3

in serious cardiovascular diseases. According to American Heart Association publication, it has been estimated
that in the US alone approximately 5.5 million people suffered from heart failure in 2013 and 300,000 die each
year because of heart failure. The market for global cardiovascular implants was valued at USD 26.1 billion in
2015 and is expected to reach around USD 39.0 billion by 2023, growing at a CAGR of 5.8% during the forecast
period of 2017 to 2023. However, there are certain restraining factors which could hamper the growth of the
market, which includes, high-risk nature and high complication rates associated with considerable mortality,
due to frequent use of implants in older populations with frequent co-morbidities. Geographically, North
America is leading contributor to the market and is expected to retain its position during the forecast period.
Nonetheless, the market for Asia-Pacific region is expected to grow at a faster rate owing to increasing
prevalence of CVD diseases, growing awareness among the population, improving healthcare infrastructure,
rise in healthcare spending, and favorable government policies.
Make an Enquiry
https://www.infiniumglobalresearch.com/reports/enquiry/83
Companies profiled:
Abbott Laboratories
B-Braun
Boston Scientific
Medtronic plc.
St. Jude Medical, Inc.
C. R. Bard, Inc.
Cook Medical
Terumo Corporation
Edwards Lifesciences
AMG International.
Infinium Global Research